Europe Gene Synthesis (Research Use) Market (By Method: Solid-phase Synthesis, Chip-based Synthesis; By Service; By Application; By End-use; By Research Phase) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

The Europe gene synthesis (research use) market was valued at USD 0.35 billion in 2022 and it is predicted to surpass around USD 1.52 billion by 2032 with a CAGR of 15.85% from 2023 to 2032.

Key Pointers

• Solid-phase synthesis segment dominated the market in 2022 with a share of 39%.
• The PCR-based enzyme synthesis method is expected to witness the fastest CAGR of 17.93% over the forecast period. 
• In the services segment, the antibody DNA synthesis segment held the largest market share of 62% in 2022.
• The viral DNA synthesis segment is expected to grow at the fastest CAGR of 18.64% during 2023-2032. 
• The gene & cell therapy development segment held a revenue share of 55% in 2022.
• The clinical segment accounted for the largest regional market share of 73% in 2022.
• The academic & government research institutions segment dominated the market with a revenue share of 43% in 2022. 
• The contract research organization end-use segment is expected to witness the fastest CAGR of 18.24% throughout the forecast period.

Report Scope of the Europe Gene Synthesis (Research Use) Market

The increasing applications of the technique in synthetic biology & genomic engineering along with technological advancements in gene synthesis methods are driving the expansion of this market. The rising adoption of gene synthesis in designing personalized medicines is projected to fuel the expansion of the regional market over the forecast period.

The COVID-19 pandemic severely impacted the gene synthesis (research use) market. Despite the economic recession due to the pandemic, the synthetic biology & gene synthesis markets have witnessed a significant increase in investments. Moreover, the market was impacted due to various research initiatives introduced based on DNA synthesis for developing treatments and vaccines for COVID-19. For instance, a study was published by the University of Oxford in which researchers evaluated the efficacy of existing synthetic plasmid DNA-based vaccines. The researchers also developed a synthetic DNA vaccine for the SARS-CoV2 virus.

The rising investments in the synthetic biology market are expected to propel the market growth over the forecast period. Due to the growing demand, investors have recently shifted their focus toward the synthesis biology industry. For instance, in 2020, eureKARE company was formed to focus on development and financing activities related to innovation in synthetic biology across Europe. Moreover, in May 2021, the company raised USD 60 million to develop microbiome and synthetic biology startups.

In addition, approximately USD 7.8 billion was invested in the synthetic biology field through public and private financing in 2020. This amount is nearly 2.5 times the funding received in 2019. The increased availability of public financing, along with the role of exchange-traded funds, has driven investments in this market. These increasing investments and funding activities can strengthen the growth over the coming years.

Over the projected period, the regional market’s growth is expected to be driven by technological advancements in DNA synthesis platforms. The launch of innovative DNA synthesis platforms with technologically cutting-edge specifications that address the increased demand of researchers is expected to support market growth. For instance, DNA Script launched the SYNTAX System in June 2021, the first benchtop nucleic acid printer based on EDS technology in the industry. The SYNTAX System is an integrated, automated printer that produces 96 DNA oligos simultaneously, each with a length of up to 60 nucleotides.

It produces it ready for use in molecular biology and genomics operations without extra processing. By enabling quick, on-site synthesis of DNA oligos for use in genomics processes such as qPCR, amplicon sequencing, endpoint PCR, and mutagenesis, DNA Script aims to speed up the development cycle for assay improvement. Such technological advancements in DNA synthesis systems can reduce the processing time and cost of DNA synthesis and sequencing, providing numerous synthesizing platforms.

Method Insights

Based on method, the market is segmented into solid-phase, chip-based, and PCR-based enzyme synthesis. Solid-phase synthesis segment dominated the market in 2022 with a share of 39% due to the presence and widespread use of this technique, along with the increasing automation in solid-phase technology, which enhanced the efficiency of DNA synthesis. A rise in the adoption of solid-phase synthesis for biophysical studies also favors segment demand.

The PCR-based enzyme synthesis method is expected to witness the fastest CAGR of 17.93% over the forecast period. The growth of the segment can be attributed to the restraints of the chemical synthesis process, such as producing desired quality DNA for only up to a limited length and the environmental impact of the harsh chemicals used.

Services Insights

In the services segment, the antibody DNA synthesis segment held the largest market share of 62% in 2022, owing to an increase in the adoption of gene synthesis in the production of antibodies used for research and the availability of cutting-edge recombinant technology. Furthermore, the increased importance of personalized antibodies and related research for cancer or genetic disorders drives the segment.

The viral DNA synthesis segment is expected to grow at the fastest CAGR of 18.64% during 2023-2032. Gene synthesis enables the construction of viral DNA in the laboratory without needing an existent virus sample. Moreover, the synthesis of viral genomes also assists in recognizing the gene functions and pathogenicity of the organism, allowing for the development of better treatment or disorder prevention options. These applications of viral DNA synthesis services are anticipated to drive the segment.

Application Insights

Based on application, the gene synthesis market is segmented into gene & cell therapy development, vaccine development, and others. The gene & cell therapy development segment held a revenue share of 55% in 2022, and it is anticipated to showcase the fastest CAGR over the forecast period. The dominance and growth of the segment can be attributed to several factors, including increasing gene & cell therapy approvals and the growing use of gene synthesis methods for cloning synthetic therapeutic genes in viral vectors. Moreover, the growing adoption of gene & cell therapies and increasing government support are anticipated to drive the segment in the coming years.

Research Phase Insights

Based on research phase, the Europe gene synthesis (research use) market is segmented into preclinical and clinical. The clinical segment accounted for the largest regional market share of 73% in 2022. The segment is also projected to display lucrative growth over the forecast period with a CACR of 17.25%. The segment's growth is expected to be driven by the increase in the number of clinical trials for advanced therapy medicinal products. In addition, biomarker discovery and disease modeling are also anticipated to propel segment growth by 2032.

End-use Insights

Based on end-use, the gene synthesis market is segmented into academic & government research institutes, biotechnology & pharmaceutical companies, and contract research organizations (CROs). The academic & government research institutions segment dominated the market with a revenue share of 43% in 2022. The segment's dominance is due to expanding research prospects aimed at exploring the use of gene synthesis for studying model organisms. Moreover, enhanced flexibility and automation in gene synthesis facilitated a growing penetration of the technique in research laboratories. Collaborations between industry and academia are expected to boost segment growth over the coming years.

The contract research organization end-use segment is expected to witness the fastest CAGR of 18.24% throughout the forecast period. The growing number of small biotechnology companies and increasing outsourcing trends are anticipated to impact segment growth in the forthcoming years.

Europe Gene Synthesis (Research Use) Market Segmentations:

By Method 

• Solid-phase Synthesis
• Chip-based Synthesis
• PCR-based Enzyme Synthesis

By Service 

• Antibody DNA Synthesis
• Viral DNA Synthesis
• Others

By Application 

• Gene & Cell Therapy Development
• Vaccine Development
• Others

By Research Phase 

• Pre-clinical
• Clinical

By End-use 

• Biotechnology and Pharmaceutical Companies
• Academic and Government Research Institutes
• Contract Research Organizations